Vonvendi is approved by the Food and Drug Administration (FDA) for on-demand treatment and control of bleeding episodes in adults with von Willebrand disease. The technical name of Vonvendi is von Willebrand factor (recombinant).
Vonvendi is a clotting factor. Clotting factors work by supplying proteins missing in people with bleeding disorders.
How do I take it?
Prescribing information states that Vonvendi is given as an intravenous injection.
Vonvendi comes as a powder that must be reconstituted before injection.
The FDA-approved label for Vonvendi lists common side effects including itching.
Rare but serious side effects listed for Vonvendi include life-threatening hypersensitivity reactions, thromboembolic events (dangerous blood clots), and the development of inhibitors.
For more details about this treatment, visit:
Treatment of Hemophilia – Hemophilia Federation of America